Benchmarking of mutation diagnostics in clinical lung cancer specimens

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Querings, Silvia ^a,b   Altmüller, Janine ^c   Ansén, Sascha ^d   Zander, Thomas ^d   Seidel, Danila ^a,b   Gabler, Franziska ^a,b   Peifer, Martin ^a   Markert, Eva ^e   Stemshorn, Kathryn ^c   Timmermann, Bernd ^f   Saal, Beate ^a   Klose, Stefan ^g   Ernestus, Karen ^e   Scheffler, Matthias ^d   Engel Riedel, Walburga ^h   Stoelben, Erich ^h   Brambilla, Elisabeth ⁱ   Wolf, Jürgen ^b,d   Nürnberg, Peter ^c   Thomas, Roman K ^a,b,d  

^a MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e Hospital Merheim   (Germany)

^f MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^g Pneumologische Gemeinschaftspraxis Dr H P Wagner Dr St Klose Dr A Kratzsch   (Germany)

^h Clinic Cologne Merheim   (Germany)

ⁱ INSTITUT ALBERT BONNIOT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; GENE DELETION; GENE FREQUENCY; GENE REPRESSION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MUTATIONAL ANALYSIS; PYROSEQUENCING; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; TISSUE TYPES; VALIDATION PROCESS; EXON; GENETICS; HUMAN GENOME; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; STANDARD; TREATMENT OUTCOME;

ADULT; AGED; BASE SEQUENCE; BENCHMARKING; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENOME, HUMAN; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 79955820904     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019601     Document Type: Article

References (33)

1. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306-13311.
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
3. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
4. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, et al. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-967.
5. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
6. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819.
7. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, et al. (2010) Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval. J Clin Oncol 28: 2512-2519.
8. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134.
9. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342-4349.
10. Smith GD, Chadwick BE, Willmore-Payne C, Bentz JS, (2008) Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis. J Clin Pathol 61: 487-493.
11. Pan Q, Pao W, Ladanyi M, (2005) Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 7: 396-403.
12. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, et al. (2005) Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 7: 413-421.
13. Nomoto K, Tsuta K, Takano T, Fukui T, Yokozawa K, et al. (2006) Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol 126: 608-615.
14. Nagai Y, Miyazawa H, Huqun, Tanaka T, Udagawa K, et al. (2005) Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65: 7276-7282.
15. Molina-Vila MA, Bertran-Alamillo J, Reguart N, Taron M, Castella E, et al. (2008) A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thorac Oncol 3: 1224-1235.
16. Miyazawa H, Tanaka T, Nagai Y, Matsuoka M, Sutani A, et al. (2008) Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation. Cancer Sci 99: 595-600.
17. Fukui T, Ohe Y, Tsuta K, Furuta K, Sakamoto H, et al. (2008) Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer. Clin Cancer Res 14: 4751-4757.
18. Felley-Bosco E, Pourzand C, Zijlstra J, Amstad P, Cerutti P, (1991) A genotypic mutation system measuring mutations in restriction recognition sequences. Nucleic Acids Res 19: 2913-2919.
19. Asano H, Toyooka S, Tokumo M, Ichimura K, Aoe K, et al. (2006) Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res 12: 43-48.
20. Thomas RK, Nickerson E, Simons JF, Janne PA, Tengs T, et al. (2006) Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 12: 852-855.
21. Sos ML, Michel K, Zander T, Weiss J, Frommolt P, et al. (2009) Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 119: 1727-1740.
22. Ronaghi M, Uhlen M, Nyren P, (1998) A sequencing method based on real-time pyrophosphate. Science 281: 363 365.
23. Li H, Durbin R, Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26: 589-595.
24. Droege M, Hill B, (2008) The Genome Sequencer FLX System-longer reads, more applications, straight forward bioinformatics and more complete data sets. J Biotechnol 136: 3-10.
25. Dufort S, Richard MJ, de Fraipont F, (2009) Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues. Anal Biochem 391: 166-168.
26. Poehlmann A, Kuester D, Meyer F, Lippert H, Roessner A, et al. (2007) K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. Pathol Res Pract 203: 489-497.
27. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, et al. (2005) Erlotinib in lung cancer- molecular and clinical predictors of outcome. N Engl J Med 353: 133-144.
28. Cappuzzo F, Ligorio C, Janne PA, Toschi L, Rossi E, et al. (2007) Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 25: 2248-2255.
29. Uramoto H, Mitsudomi T, (2007) Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer 96: 857-863.
30. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, et al. (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: e17.
31. Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, et al. (2011) Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations. Clin Cancer Res 17: 1160-1168.
32. Brevet M, Arcila M, Ladanyi M, (2010) Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 12: 169-176.
33. Oh YH, Kim Y, Kim YP, Seo SW, Mitsudomi T, et al. (2010) Rapid detection of the epidermal growth factor receptor mutation in non-small-cell lung cancer for analysis of acquired resistance using molecular beacons. J Mol Diagn 12: 644-652.